UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats

Neuron (Cambridge, Mass.), 2019-04, Vol.102 (1), p.105-119.e8

2019

Volltextzugriff (PDF)

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells

Molecular cancer therapeutics, 2004-06, Vol.3 (6), p.715-725

2004

Volltextzugriff (PDF)

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

BMC cancer, 2016-11, Vol.16 (1), p.907, Article 907

2016

Volltextzugriff (PDF)

Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine

Free radical biology & medicine, 2008-09, Vol.45 (5), p.578-584

2008

Volltextzugriff (PDF)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Cancer medicine (Malden, MA), 2016-04, Vol.5 (4), p.676-683

2016

Volltextzugriff (PDF)

Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells

Lung cancer (Amsterdam, Netherlands), 2010-05, Vol.68 (2), p.154-160

2010

Volltextzugriff (PDF)

PEPCOL : a GERCOR randomized phase II study of nanoliposomal irinotecan PEP 02 ( MM ‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Cancer medicine (Malden, MA), 2016-04, Vol.5 (4), p.676-683

2016

Volltextzugriff (PDF)

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-κB activity in drug-sensitive MCF-7 cells

Anti-cancer drugs, 2005-02, Vol.16 (2), p.137-143

2005

Volltextzugriff (PDF)

Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat

The Journal of immunology (1950), 1992-09, Vol.149 (5), p.1723-1728

1992

Volltextzugriff (PDF)

Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury

The Journal of immunology (1950), 1992-03, Vol.148 (5), p.1479-1485

1992

Volltextzugriff (PDF)

A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation

Xenotransplantation (Københaven), 2002-03, Vol.9 (2), p.125-134

2002

Volltextzugriff (PDF)

Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats

The Journal of immunology (1950), 1991-01, Vol.146 (1), p.250-256

1991

Volltextzugriff (PDF)

Abstract C207: Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.C207-C207

2011

Volltextzugriff (PDF)

Role of C3 cleavage in monocyte activation during extracorporeal circulation

Circulation (New York, N.Y.), 1999-08, Vol.100 (5), p.553-558

1999

Volltextzugriff (PDF)

The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis

Journal of the American Society of Nephrology, 1995-05, Vol.5 (11), p.1888-1894

1995

Volltextzugriff (PDF)

A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities

The Journal of immunology (1950), 1997-03, Vol.158 (6), p.2872-2881

1997

Volltextzugriff (PDF)

A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation

Transplantation, 2000-06, Vol.69 (11), p.2282

2000

Volltextzugriff (PDF)

The effect of soluble complement receptor type 1 on hyperacute xenograft rejection

Transplantation, 1991-11, Vol.52 (5), p.868-872

1991

Volltextzugriff (PDF)

Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine

The Journal of immunology (1950), 1992-05, Vol.148 (10), p.3086-3092

1992

Volltextzugriff (PDF)

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells

Anti-cancer drugs, 2005-02, Vol.16 (2), p.137-143

2005

Volltextzugriff (PDF)

Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass

The Annals of thoracic surgery, 1993-03, Vol.55 (3), p.619-624

1993

Volltextzugriff (PDF)

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-??B activity in drug-sensitive MCF-7 cells

Anti-cancer drugs, 2005-02, Vol.16 (2), p.137-143

2005

Volltextzugriff (PDF)

Role of complement in endotoxin/platelet-activating factor-induced lung injury

The Journal of immunology (1950), 1992-09, Vol.149 (5), p.1744-1750

1992

Volltextzugriff (PDF)

(±)-trans-2-[3-Methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a Potent Dual 5-Lipoxygenase Inhibitor and Platelet-Activating Factor Receptor Antagonist

Journal of medicinal chemistry, 1998-05, Vol.41 (11), p.1970-1979

1998

Volltextzugriff (PDF)

A RECOMBINANT SOLUBLE CHIMERIC COMPLEMENT INHIBITOR COMPOSED OF HUMAN CD46 AND CD55 REDUCES ACUTE CARDIAC TISSUE INJURY IN MODELS OF PIG-TO-HUMAN HEART TRANSPLANTATION1, 2

Transplantation, 2000-06, Vol.69 (11), p.2282-2289

2000

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(93)
Bücher
(1)

Sprache

Englisch
(94)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(78)
Life Sciences & Biomedicine
(71)
Humans
(53)
Biological And Medical Sciences
(31)
Medical Sciences
(25)
Animals
(23)
Female
(22)
Male
(21)
Oncology
(21)
Tumor Cells, Cultured
(17)
Tumors
(14)
Immunology
(13)
Rats
(13)
Biochemistry & Molecular Biology
(12)
Adult
(10)
Carcinogenesis, Carcinogens And Anticarcinogens
(10)
Rna, Messenger - Metabolism
(9)
Cytochrome P-450 Cyp1a1 - Metabolism
(8)
Mice
(8)
Receptors, Aryl Hydrocarbon - Metabolism
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats

Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

Generation of nitroxyl by heme protein-mediated peroxidation of hydroxylamine but not N-hydroxy-L-arginine

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells

PEPCOL : a GERCOR randomized phase II study of nanoliposomal irinotecan PEP 02 ( MM ‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-κB activity in drug-sensitive MCF-7 cells

Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat

Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury

A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation

Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats

Abstract C207: Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan

Role of C3 cleavage in monocyte activation during extracorporeal circulation

The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis

A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities

A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation

The effect of soluble complement receptor type 1 on hyperacute xenograft rejection

Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells

Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass

The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-??B activity in drug-sensitive MCF-7 cells

Role of complement in endotoxin/platelet-activating factor-induced lung injury

(±)-trans-2-[3-Methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a Potent Dual 5-Lipoxygenase Inhibitor and Platelet-Activating Factor Receptor Antagonist

A RECOMBINANT SOLUBLE CHIMERIC COMPLEMENT INHIBITOR COMPOSED OF HUMAN CD46 AND CD55 REDUCES ACUTE CARDIAC TISSUE INJURY IN MODELS OF PIG-TO-HUMAN HEART TRANSPLANTATION1, 2

Suchergebnisse filtern